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[Introductory paragraph] 21 
 22 
Mutations of the mitochondrial genome (mtDNA) underlie a significant portion of 23 
mitochondrial disease burden. These disorders are currently incurable and effectively 24 
untreatable, with heterogeneous penetrance, presentation and prognosis. To address 25 
the lack of effective treatment for these disorders, we exploited a recently developed 26 
mouse model that recapitulates common molecular features of heteroplasmic mtDNA 27 
disease in cardiac tissue, the m.5024C>T tRNAALA mouse. Through application of a 28 
programmable nuclease therapy approach, using systemically administered, 29 
mitochondrially targeted zinc finger-nucleases (mtZFNs) delivered by adeno-associated 30 
virus, we induced specific elimination of mutant mtDNA across the heart, coupled to a 31 
reversion of molecular and biochemical phenotypes. These findings constitute proof-of-32 
principle that mtDNA heteroplasmy correction using programmable nucleases could 33 
provide a therapeutic route for heteroplasmic mitochondrial diseases of diverse genetic 34 
origin. 35 
 36 
[Introduction] 37 
 38 
Mitochondrial diseases are a broad group of hereditary, multi-system disorders, a 39 
substantial portion of which are transmitted through mutations of mitochondrial DNA 40 
(mtDNA) with minimum prevalence of 1 in 5,000 adults 1. Human mtDNA is a small, 41 
double-stranded, multi-copy genome present at ~ 100 – 10,000 copies per cell 2. In the 42 
disease state, mutated mtDNA often co-exists with wild-type mtDNA in heteroplasmy, 43 
and disease severity in conditions caused by heteroplasmic mtDNA mutations 44 
correlates with mutation load 3. A threshold effect, where > 60% mutant mtDNA load 45 
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must be exceeded before symptoms manifest, is a definitive feature of heteroplasmic 46 
mtDNA diseases, and attempts to shift the heteroplasmic ratio below this threshold have 47 
driven much research towards treatment of these incurable and essentially untreatable 48 
disorders. One such approach relies on directed nucleolysis of mtDNA using, among 49 
other programmable genome engineering tools, mitochondrially targeted zinc finger-50 
nucleases (mtZFNs) 4-6. Because mammalian mitochondria lack efficient DNA double-51 
strand break (DSB) repair pathways 7, selective introduction of DSBs into mutant 52 
mtDNA leads to rapid degradation of these molecules by components of the mtDNA 53 
replisome 8. As mtDNA copy number is maintained at a cell type-specific steady-state 54 
level, selective elimination of mutant mtDNA stimulates replication of the remaining 55 
mtDNA pool, eliciting shifts in the heteroplasmic ratio. 56 
 In previous work, we have described methods for delivery of zinc finger proteins 57 
(ZFPs) to mitochondria in cultured cells 9,10 and the assembly and function of efficient 58 
mtZFN architectures, capable of producing large heteroplasmic shifts that result in 59 
phenotype rescue of patient-derived cell cultures 5,11-13. Using the first available mouse 60 
model of heteroplasmic mitochondrial disease, bearing the point mutation m.5024C>T 61 
in mitochondrial tRNAALA (mt-tRNAALA), which faithfully recapitulates key molecular 62 
features of mitochondrial disorders in cardiac tissue 14, we now demonstrate efficient 63 
manipulation of mtDNA heteroplasmy with concomitant rescue of molecular and 64 
biochemical phenotypes across the heart following delivery of mtZFNs by systemically 65 
administered adeno-associated virus (AAV). 66 
 67 
[Results] 68 
 69 
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In the context of second generation tail-tail mtZFN architectures (mtZFN2G) shown to be 70 
efficacious in previous work 5,15, we set out to generate pairs of zinc finger proteins 71 
(ZFP) with single nucleotide binding specificity for m.5024C>T. As this site in the mouse 72 
mtDNA is challenging for ZFPs, a selection of targeting strategies with varying numbers 73 
of zinc finger motifs, spacer region lengths and additional linkers were employed. 74 
Assembly of candidate ZFPs yielded a library (Fig. S1A and Table S1) consisting of 24 75 
unique ZFPs targeting the m.5024C>T site, referred to as mutant-specific monomer 76 
(MTM), and a single partner ZFP targeting an adjacent sequence on the opposite 77 
strand, referred to as wild-type-specific monomer 1 (WTM1). These constructs were 78 
subjected to several rounds of screening in mouse embryonic fibroblasts (MEFs) 79 
bearing ~ 65% m.5024C>T to assess heteroplasmy shifting activity (Fig. S1B). These 80 
screens identified consistent, specific activity of pairing MTM25/WTM1 (Fig. S1C and 81 
Fig. 1A), which produced a shift of ~ 20%, from 65% to 45% m.5024C>T in the MEF 82 
cell line as determined by pyrosequencing (Fig. 1B). We additionally confirmed 83 
exclusive mitochondrial localization of MTM25 and WTM1 in MEF cells (Fig. S2), and 84 
then selected this pair for in vivo experiments. 85 
 MTM25 and WTM1 mtZFN monomers were encoded in separate viral genomes 86 
and encapsidated within the cardiac-tropic, engineered AAV9.45 serotype (Fig. 1C) 16. 87 
Following tail-vein administration of 5*1012 viral genomes (vg) per monomer per mouse, 88 
robust expression of MTM25 and WTM1 in total mouse heart tissue was detected by 89 
western blotting (Fig. 1D). Despite equal quantities of injected viral genomes, lower 90 
expression levels of WTM1 were consistently detected, possibly due to lower stability of 91 
the translated protein. Next, various doses of mtZFN-AAV9.45 were administered into 92 
mt-tRNAALA animals harbouring m.5024C>T heteroplasmy ranging from 44 % - 81 % 93 
(Table S2). As only minimal variance in heteroplasmy is observed between tissues of 94 
Nature Medicine - Letter 
 5
the m.5024C>T mouse13, mtDNA heteroplasmy is assessed by comparison of 95 
pyrosequencing data, expressed as the change (∆) between ear punch genotype (E) 96 
determined at two weeks of age (prior to experimental intervention) and post-mortem 97 
heart genotype (H). Analysis of animals at 65 days post-injection revealed specific 98 
elimination of the m.5024C>T mutant mtDNA in mtZFN-treated mice, but not in vehicle- 99 
or single monomer-injected controls (Fig. 1E). The extent to which heteroplasmy was 100 
altered by mtZFN treatment followed a biphasic AAV dose-dependent trend, with the 101 
intermediate dose (5*1012 vg) being the most efficient in eliminating m.5024C>T mutant 102 
mtDNA (Fig. 1E). The lowest (1*1012 vg) dose did not result in heteroplasmy shifts (Fig. 103 
1E), due to insufficient concentration of mtZFNs and mosaic transduction of the targeted 104 
tissue by AAV (Fig. S3). The highest dose (1*1013 vg) exhibited diminished 105 
heteroplasmy shifting activity compared with the intermediate dose (5*1012 vg), likely 106 
due to mitochondrial off-target effects resulting in partial mtDNA copy number 107 
depletions, which are not observed when lower doses are administered (Fig. 1F). It is 108 
unclear what effect, if any, these partial depletions of mtDNA copy number could exert 109 
over time, however this lattermost result is consistent with our previous observations 12, 110 
underscoring the importance of fine-tuning mtZFN levels in mitochondria for efficient 111 
mtDNA heteroplasmy modification. AAV9.45 transduction could not be detected in non-112 
cardiac tissues, and no shifts in heteroplasmy were detected in the liver at 65 days post-113 
injection, irrespective of viral dose (Fig. S3). As AAV transduction of post-mitotic 114 
tissues, particularly in short-lived mammals, is essentially permanent, a time-115 
dependence of heteroplasmy shifting is expected. Accordingly, measurements of 116 
mtDNA heteroplasmy over time in cardiac tissue demonstrate significant increases in 117 
heteroplasmy shifting activity in the latest post-treatment time points (Fig. S4). Despite 118 
the presence of two regions with significant homology to the mtDNA target site in the 119 
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nuclear genome, no evidence for off-target effects exerted by mtZFNs could be 120 
detected at these sites (Fig. S5A,B), consistent with our previous reports of exclusive 121 
mitochondrial localization of mtZFNs 5,9,10,12. Additionally, no evidence for non-122 
homologous end-joining (NHEJ) at the target site in mtDNA could be detected, 123 
confirming previous data that mtZFN-induced DNA DSBs do not result in NHEJ activity 124 
(Fig. S5C) 12.  125 
Having defined conditions within which a robust shift of m.5024C>T 126 
heteroplasmy is achieved in vivo, we next addressed disease-relevant phenotype 127 
correction in the model. A common feature of mt-tRNA mutations in mitochondrial 128 
diseases, recapitulated in the tRNAALA mouse model 14, is the instability of mt-tRNA 129 
molecules in proportion with mutant load (Fig. 2A) 17. To assess the effects of mtZFN 130 
treatment on the stability of mt-tRNAALA in the hearts of animals across the dosage 131 
range, we used high-resolution northern blotting, which revealed a significant increase 132 
in mt-tRNAALA steady-state levels (Fig. 2B and Fig. S6) that are proportional to 133 
heteroplasmy shifts detected in these mice (average m.5024C>T heteroplasmy: control 134 
71% pre-, 73% post-treatment; low AAV dose, 73% pre-, 71% post-treatment; medium 135 
AAV dose, 73% pre-, 37% post-treatment; high AAV dose, 71% pre-, 40% post-136 
treatment) (Fig. 1E and Table S2) and consistent with previously reported data 14. 137 
Depletions of mtDNA copy number associated with administration of high viral doses 138 
(Fig. 1F), did not appear to impact recovery of mt-tRNAALA steady-state levels following 139 
heteroplasmy shift (Fig. 2B). This agrees with previously published data that even 140 
severe mtDNA depletion does not manifest in proportional changes of mitochondrial 141 
RNA steady-state levels 18.  142 
To assess the physiological effects of mt-tRNAALA molecular phenotype rescue, 143 
we analyzed steady-state metabolite levels in cardiac tissue from mice with high 144 
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m.5024C>T mutant heteroplasmy treated with the intermediate viral titer (5*1012 vg) and 145 
heteroplasmy/age matched controls (Table S2). This analysis revealed an altered 146 
metabolic signature in mtZFN treated mice (Fig. 2C and Fig. S7), demonstrating 147 
significantly increased pyruvate levels (Fig. 2D) and significantly decreased lactate 148 
levels (Fig. 2E) in treated mice, suggestive of a diminished reliance on glycolysis, 149 
coupled to elevated aspartate levels (Fig. 2F) in treated mice, suggestive of improved 150 
mitochondrial respiration 19. These indicators of improved mitochondrial metabolism are 151 
not observed in mice treated with the highest AAV dose (Fig. S8), which also exhibit 152 
substantial copy number depletions (Fig. 1F). Due to phenotypic heterogeneity of mice 153 
bearing high levels of mtDNA heteroplasmy, changes in gross cardiac function following 154 
heteroplasmic shifts could not be assessed. Taken together, these data indicate that 155 
partial m.5024C>T heteroplasmy shift (Fig. 1E) results in recovery of mt-tRNAALA 156 
steady-state levels and rescue of mitochondrial function (Fig. 2C-F). 157 
 158 
[Discussion] 159 
 160 
Our previous reports on the use of mtZFN technology have demonstrated that these 161 
programmable nucleases can target multiple genetic lesions, producing phenotypically 162 
relevant shifts of mtDNA heteroplasmy in cellular models of mitochondrial dysfunction 163 
5,12,13. Here, we have further demonstrated the flexibility and future potential of mtZFN 164 
technology by targeting another heteroplasmic mutation in mouse mtDNA, m.5024C>T, 165 
manipulating the heteroplasmy of this variant both in vitro and in vivo (Fig. 1), which 166 
results in molecular and physiological rescue of disease phenotypes in heart tissue 167 
(Fig. 2).  168 
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 Despite the time elapsed since mtDNA mutations were first associated with 169 
human disease in the late 1980’s 20,21, effective treatments for heteroplasmic 170 
mitochondrial disease have not been forthcoming. Preventing the transmission of 171 
mtDNA mutations through mitochondrial replacement therapy/mitochondrial donation 172 
has gained traction 22,23, although given the nature of the mtDNA bottleneck 24, issues 173 
surrounding carryover of mutant mtDNA 25, heterogeneous mitochondrial disease 174 
presentation 26 and the subsequent lack of family history of mitochondrial disease in the 175 
majority of new cases, these approaches can only be of limited use. More recently, 176 
several intriguing molecular pathways to treatment of mitochondrial disease have been 177 
defined and explored by a number of groups 27, however, hopes for clinically-relevant 178 
therapy for heteroplasmic mitochondrial disease, thus far, remain unfulfilled 28. The data 179 
we describe in this letter, and those from Bacman et al. 29, constitute proof-of-principle 180 
that somatic mitochondrial genome editing using programmable nucleases, in 181 
combination with the ever-increasing collection of engineered, tissue-specific AAV 182 
serotypes, may offer a potentially universal route to treatment for heteroplasmic 183 
mitochondrial disease. Given the magnitude of in vivo heteroplasmy modification 184 
demonstrated using these tools, total amelioration of clinical symptoms and/or halting of 185 
disease progression could be expected. As such, this development has the potential to 186 
transform the prospects of many mitochondrial disease patients, and further work 187 
enabling the translation of these tools into effective medicines is vital.  188 
 189 
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[Figure Legends] 320 
 321 
Figure 1. Strategy to eliminate m.5024C>T and in vivo mtDNA heteroplasmy 322 
modification. A Illustration of mtZFN strategy. A wild-type specific monomer (WTM1), 323 
bind upstream of m.5024 in wild-type and mutant genomes; a mutant specific monomer 324 
(MTM25) binds preferentially to the mutated site. Dimerization of obligatory 325 
heterodimeric FokI domains produces DNA double-stand breaks resulting in specific 326 
depletion of mutant mtDNA. B Pyrosequencing of m.5024C>T heteroplasmy from MEFs 327 
transfected with controls or MTM25/WTM1 at differing concentrations facilitated by 328 
tetracycline-sensitive HHR 12. Change (∆) in m.5024C>T heteroplasmy is plotted. utZFN 329 
is a mtZFN that does not have a target site in mouse mtDNA 12. n = 5 (mtZFN, low 330 
expression), 8 (mtZFN, high expression), 4 (all other conditions) biologically 331 
independent cell cultures (Table S2). Error bars indicate SD. Statistical analysis 332 
performed: two-tailed Student’s t-test. Vehicle/mtZFN low expression p = 0.000021, 333 
vehicle/mtZFN high expression p = 0.000083. Measure of center is the mean. C 334 
Scheme of in vivo experiments. MTM25 and WTM1 are encoded in separate AAV 335 
genomes, encapsidated in AAV9.45 then simultaneously administered by tail-vein (TV) 336 
injection. Animals are sacrificed at 65 days post-injection. D Western blot of total heart 337 
protein from animals injected with 5*1012 vg MTM25 and/or WTM1. Both proteins 338 
include the HA tag and are differentiated by molecular weight. This blot was performed 339 
twice with similar results. Raw data are available for this panel (Fig. S9). E 340 
Pyrosequencing of m.5024C>T heteroplasmy from ear [E] and heart [H] total DNA. 341 
Change (∆) in m.5024C>T is plotted. n = 20 (vehicle), 3 (WTM1 only), 4 (all other 342 
conditions) animals (Table S2). Error bars indicate SEM. Statistical analysis performed: 343 
two-tailed Student’s t-test. Vehicle/intermediate dose p < 0.00001, Vehicle/high dose p 344 
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< 0.00001. Measure of center is the mean. F Assessment of mtDNA copy number by 345 
qPCR. n = 8 (vehicle), 4 (all other conditions) animals (Table S2). Error bars indicate 346 
SEM. Statistical analysis performed: two-tailed Student’s t-test p = 0.007931. Measure 347 
of center is the mean. 348 
 349 
Figure 2. Reduction of m.5024C>T mtDNA heteroplasmy results in phenotype rescue. 350 
A Illustration of mt-tRNAALA bearing the m.5024C>T mutation. Given the nature and 351 
position of this mutation, transcribed tRNA molecules containing the mutation mispair 352 
are unlikely to fold correctly or be aminoacylated, resulting in reduced steady-state 353 
levels of mt-tRNAALA at high levels of m.5024C>T heteroplasmy 14. B Quantification of 354 
high-resolution northern blot data from total heart RNA extracts. mt-tRNAALA and mt-355 
tRNACYS abundance was normalized to 5S rRNA. n = 8 (vehicle), 4 (all other conditions) 356 
animals (Table S2). Error bars indicate SEM. Statistical analysis performed: two-tailed 357 
Student’s t-test. Vehicle/intermediate dose p < 0.00001, vehicle/high dose p = 0.00011. 358 
Measure of center is the mean. C Principal component analysis (PCA) plot of 359 
metabolomic data for intermediate dose AAV-treated mice and age/initial heteroplasmy-360 
matched controls acquired by LC-MS (Table S2). n = 3 (vehicle), 4 (AAV) animals. D 361 
Total metabolite levels of pyruvate from samples measured in C. n = 3 (vehicle), 4 362 
(AAV) animals. Error bars indicate SEM. Statistical analysis performed: one-tailed 363 
Student’s t-test. p = 0.046403. Measure of center is the mean. E Total metabolite levels 364 
of lactate from samples measured in C. n = 3 (vehicle), 4 (AAV) animals. Error bars 365 
indicate SEM. Statistical analysis performed: one-tailed Student’s t-test. p = 0.03505. 366 
Measure of center is the mean. E Total metabolite levels of aspartate from samples 367 
measured in C. Error bars indicate SEM. n = 3 (vehicle), 4 (AAV) animals. Measure of 368 
center is the mean 369 
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 370 
 371 
 372 
[Online Methods] 373 
 374 
Constructs, plasmids and viral vectors 375 
All mtZFN architectures used were as reported for second generation mtZFN 376 
(mtZFN2G), with the exception of the ZFP domains 5,15. The MTM(n)_T2A_WTM1 377 
m.5024C>T candidate library was cloned by insertion of the MTM ZFP domains 378 
upstream of FokI(+) between 5’ EcoRI and 3’ BamHI restriction sites. This product was 379 
then PCR amplified to include a 5’ ApaI site and remove the 3’ stop codon while also 380 
incorporating a T2A sequence and 3’ XhoI site. This fragment was then cloned into 381 
pcmCherry (Addgene 62803) using ApaI/XhoI sites. The WTM1 ZFP was separately 382 
cloned upstream of FokI(-) in the pcmCherry_3k19 vector (Addgene 104499) 383 
incorporating the 3’ hammerhead ribozyme (HHR) using 5’ EcoRI and 3’ BamHI sites, 384 
and the resulting product was PCR amplified to include 5’ XhoI and 3’ AflII sites allowing 385 
cloning downstream of MTM(n) variants. MTM25(+) and WTM1(-) monomers were 386 
cloned into separate pcmCherry and pTracer vectors as described previously 15. Vector 387 
construction of mtZFNs intended for AAV production was achieved by PCR 388 
amplification of MTM25(+)_HHR and WTM1(-)_HHR transgenes, incorporating 5’ EagI 389 
and 3’ BglII sites. These products were then cloned into rAAV2-CMV between 5’ EagI 390 
and 3’ BamHI sites. The FLAG epitope tag of WTM1(-) was replaced with a 391 
hemagglutinin (HA) tag at the same position in the WTM1(-) open reading frame by 392 
PCR. The resulting plasmids were used to generate recombinant AAV2/9.45-CMV-393 
MTM25 and AAV2/9.45-CMV-WTM1 viral particles at the UNC Gene Therapy Center, 394 
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Vector Core Facility (Chapel Hill, NC). The 3K19 hammerhead ribozyme (HHR) 395 
sequence 30 was incorporated into mtZFN-AAV9.45 constructs to allow ubiquitous 396 
expression of the transgene from CMV while limiting the expression level, allowing 397 
administration of the high viral titers required to ensure effective co-transduction of cells 398 
in the targeted tissue without inducing large mtDNA copy number depletions. 399 
 400 
Maintenance, transfection and fluorescence activated cell sorting of cell cultures 401 
Wild-type and m.5024C>T mouse embryonic fibroblast (MEF) cell lines were cultured in 402 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 2 mM L-glutamine, 110 mg/L 403 
sodium pyruvate (Life Technologies) and 10% FCS (PAA Laboratories). Cells were 404 
transfected by electroporation using Nucleofector II apparatus (Lonza) using a MEF1 kit 405 
and T20 program. Fluorescence activated cell sorting (FACS) was performed as 406 
described previously 15. Control of mtZFN expression was achieved through titration of 407 
tetracycline into culture media, controlling the rate of HHR autocatalysis as described 408 
previously 12.  409 
 410 
Use of animal models 411 
All animal experiments were carried out in accordance with the UK Animals (Scientific 412 
Procedures) Act 1986 (PPL70/7538) and EU Directive 2010/63/EU. The C57BL/6j-413 
tRNAALA mice used in this study were housed from one to four per cage in a 414 
temperature controlled (21°C) room with a 12 h light-dark cycle and 60% relative 415 
humidity. The experimental design included only male mice between 2 to 8 months of 416 
age harboring 44 % - 81 % m.5024C>T heteroplasmy (20 Vehicle, 7 Single Monomer, 4 417 
per mtZFN-AAV9.45 dosage) (Table S1). Treatments of vehicle (1 x PBS, 350 mM 418 
NaCl, 5% w/v D-sorbitol) and AAVs were administered by tail vein injection.   419 
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 420 
Protein extraction and quantitation 421 
For cultured cells, total cellular protein was extracted as described previously 12. For 422 
mouse heart tissue, 50 mg was homogenised in RIPA buffer (150 mM NaCl, 50 mM Tris 423 
pH 8, 1% (v/v) Triton X-100, 0.5% (v/v) deoxycholate, 0.1% (v/v) SDS) using a 424 
gentleMACS dissociator (Miltenyi). The resulting homogenate was centrifuged at 10,000 425 
x g at 4C for 10 minutes, supernatant was then recovered and centrifuged at 10,000 x g 426 
at 4C for 10 minutes. Concentration of both cellular and tissue protein extracts was 427 
determined by BCA assay (Pierce). 428 
 429 
Immunodetection of proteins 430 
The localization of proteins by immunofluorescence in fixed MEF cells was performed 431 
as described previously 10. The following antibodies were used: rabbit anti-TOM20 432 
(Santa Cruz Biotechnology, sc-11415, 1:200), Alexa Fluor 647 anti-rabbit (Abcam, 433 
ab150079, 1:1000), mouse anti-FLAG (Sigma, F1804, 1:1000), Alexa Fluor 594 anti-434 
mouse (Life Technologies, R37121, 1:1000), rat anti-HA (Roche, 11867431001, 1:200), 435 
Alexa Fluor 488 anti-rat (Life Technologies, A11006). Immunofluorescence images were 436 
captured using a Zeiss LSM880 confocal microscope and processed using ImageJ. 437 
 438 
Detection of proteins by western blotting was achieved by resolving 20-100 μg of 439 
extracted protein on SDS-PAGE 4-12% Bis-Tris Bolt gels. These were transferred to 440 
nitrocellulose using an iBlot 2 transfer cell (Life Technologies). Antibodies used for 441 
western blotting in this work: rat anti-HA (Roche, 11867431001, 1:500), goat anti-rat 442 
HRP (Santa Cruz, SC2065, 1:1000). Gels were stained for loading using Coomassie 443 
Brilliant Blue (Life Technologies). 444 
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 445 
 446 
Tissue histology and fluorescence microscopy 447 
To evaluate GFP expression in histological sections, mouse tissues (heart, liver, brain, 448 
kidney and skeletal muscles) were snap-frozen in isopentane pre-cooled in liquid 449 
nitrogen. Eight μm-thick sections on positive-charged glass slides were fixed in 4% 450 
PFA, washed with PBS and finally mounted with Prolong Diamond Antifade Mountant 451 
with DAPI. Images were acquired using a Zeiss Axio Observer Z1 microscope LSM 880 452 
confocal module, equipped with an Argon Ion MultiLine Laser, Solid State Diode Laser 453 
(405 nm), AOTF filter, and a Plan-Apochromat 63x/1.4 NA oil immersion objective). All 454 
settings were preserved during image acquisition for all samples. Image J was used to 455 
process the images.  456 
 457 
DNA extraction and quantitation 458 
DNA was extracted from both cultured cells and whole tissues using a Qiagen DNEasy 459 
Blood & Tissue kit, according to the manufacturer’s instructions. Once acquired, DNA 460 
concentrations were assessed by spectrophotometry. 461 
 462 
Pyrosequencing and qPCR 463 
Assessment of m.5024C>T mtDNA heteroplasmy was carried out by pyrosequencing. 464 
PCR reactions for pyrosequencing were prepared using KOD DNA polymerase (Takara) 465 
for 40 cycles using 100 ng template DNA with the following primers: 466 
 467 
m.4,962 – 4,986 Forward 468 
5’ ATACTAGTCCGCGAGCCTTCAAAG 3’ 469 
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 470 
m.5,360 – m.5,383 Reverse 471 
5’ [Btn] GAGGGTTCCGATATCTTTGTGATT 3’ 472 
 473 
m.5003 – m.5022  Sequencing primer 474 
5’ AAGTTTAACTTCTGATAAGG 3’ 475 
 476 
Mitochondrial DNA copy number of mouse heart samples was determined by qPCR 477 
using PowerUp SYBR Green Master Mix according to the manufacturer’s protocol 478 
(Applied Biosystems). Samples were analysed using a 7900HT Fast Real-Time PCR 479 
System (Thermo Fisher). The following primers were used:  480 
 481 
 MT-COI Forward 482 
5’ TGCTAGCCGCAGGCATTACT 3’ 483 
 484 
MT-COI Reverse 485 
5’ CGGGATCAAAGAAAGTTGTGTTT 3’ 486 
 487 
RNaseP Forward  488 
5’ GCCTACACTGGAGTCCGTGCTACT 3’  489 
 490 
RNaseP Reverse 491 
5’ CTGACCACACACGAGCTGGTAGAA 3’ 492 
 493 
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All primers for pyrosequencing and qPCR were designed using NCBI reference 494 
sequences GRCm38.p6 and NC_005089.1 for the C57BL/6j mouse nuclear and 495 
mitochondrial genomes respectively.  496 
 497 
Amplicon resequencing of nuclear DNA off-target sites  498 
Two regions of the NCBI reference sequence for C57BL/6j nuclear DNA demonstrated 499 
significant homology (>75% sequence identity) with the mtZFN target site in mtDNA. 500 
Amplicons containing these sites were obtained by PCR using primers listed below: 501 
 502 
Ch.2 Forward 503 
5’ GGGTTCCGATATCTTTGTGATTGG 3’ 504 
 505 
Ch.2 Reverse 506 
5’ GAGCATAAGCCATTGTTGTTCTG 3’ 507 
 508 
Ch.5 Forward 509 
5’ GACTACCTGAGCAAGGAGTC 3’ 510 
 511 
Ch.5 Reverse 512 
5’ CTACAGGAGATGGAGGACAC 3’ 513 
 514 
All primers were designed using NCBI reference sequence GRCm38.p6 for the 515 
C57BL/6j mouse nuclear genome. PCR amplicons were subjected to Nextera sample 516 
processing, and resulting libraries were assessed by 2 x 150-cycle paired-end 517 
sequencing using a MiSeq instrument (Illumina). Quality trimming and 3’-end adapter 518 
clipping of sequenced reads were performed simultaneously with Trim Galore! (--paired) 519 
and aligned to GRCm38 using bowtie2. Only reads that contained the entire region 520 
chr5: 60042834-60042934 or chr2: 22589909-22590009 were selected for counting with 521 
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SAMtools (flagstat) and insertion/deletion count based on CIGAR string (I/D). All 522 
individual samples yielded >10,000 reads per nucleotide.  523 
 524 
Amplicon resequencing of the mtDNA target site  525 
The region m.4,962 - 5,383, also used for pyrosequencing analysis, was amplified by 526 
PCR using un-biotinylated primers. PCR amplicons were subjected to Nextera sample 527 
processing, and resulting libraries were assessed by 2 x 150-cycle paired-end 528 
sequencing using a MiSeq instrument (Illumina). Quality trimming and 3’-end adapter 529 
clipping of sequenced reads were performed simultaneously with Trim Galore! (--paired) 530 
and aligned to GRCm38 using bowtie2. Only reads that contained the entire region 531 
m.4,994 – 5,094 were selected for counting with SAMtools (flagstat) and 532 
insertion/deletion count based on CIGAR string (I/D). All individual samples yielded 533 
>10,000 reads per nucleotide.  534 
 535 
RNA extraction and northern blotting 536 
Total RNA was extracted from 25 mg of mouse heart tissue using Trizol (Ambion) by 537 
homogenization using a gentleMACS dissociator (Miltenyi). Northern blotting was 538 
performed as described previously 31. Briefly, 5 µg of total RNA was resolved on a 10 % 539 
(w/v) polyacrylamide gel containing 8 M urea. Gels were dry blotted onto a positively 540 
charged nylon membrane (Hybond-N+), with the resulting membrane cross-linked by 541 
exposure to 254 nm UV light, 120 mJ/cm2. For tRNA probes, cross-linked membranes 542 
were hybridised with radioactively labelled RNA probes T7 transcribed from PCR 543 
fragments corresponding to appropriate regions of mouse mtDNA. 5S rRNA was probed 544 
with a complementary α[32P]-end labelled DNA oligo. Membranes were exposed to a 545 
storage phosphor screen and scanned using a Typhoon phosphor imaging system (GE 546 
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Healthcare). The signals were quantified using Fiji software. The following 547 
primers/oligonucleotides were used: 548 
 549 
MT-TA Forward 550 
5’ TAATACGACTCACTATAGGGAGACTAAGGACTGTAAGACTTCATC 3’ 551 
 552 
MT-TA Reverse 553 
5’ GAGGTCTTAGCTTAATTAAAG 3’ 554 
 555 
MT-TC Forward 556 
5’ TAATACGACTCACTATAGGGAGACAAGTCTTAGTAGAGATTTCTC 3’ 557 
 558 
MT-TC Reverse 559 
5’ GGTCTTAAGGTGATATTCATG 3’ 560 
 561 
MT-TL1 Forward 562 
5’ TAATACGACTCACTATAGGGAGACTATTAGGGAGAGGATTTGAAC 3’ 563 
 564 
MT-TL1 Reverse 565 
5’ ATTAGGGTGGCAGAGCCAGG 3’ 566 
 567 
5S rRNA oligo: 568 
5’ AAGCCTACAGCACCCGGTATTCCCAGGCGGTCTCCCATCCAAGTACTAACCA 3’ 569 
 570 
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All primers for northern blotting were designed using NCBI reference sequences 571 
GRCm38.p6 and NC_005089.1 for the C57BL/6j mouse nuclear and mitochondrial 572 
genomes respectively.  573 
 574 
Sample preparation and liquid chromatography coupled to mass spectrometry (LC-MS) 575 
analysis 576 
Snap-frozen tissue specimens were cut and weighed into Precellys tubes prefilled with 577 
ceramic beads (Stretton Scientific Ltd., Derbyshire, UK). An exact volume of extraction 578 
solution (30% acetonitrile, 50% methanol and 20% water) was added to obtain 40 mg 579 
specimen per mL of extraction solution. Tissue samples were lysed using a Precellys 24 580 
homogenizer (Stretton Scientific Ltd., Derbyshire, UK). The suspension was mixed and 581 
incubated for 15 minutes at 4°C in a Thermomixer (Eppendorf, Germany), followed by 582 
centrifugation (16,000 g, 15 min at 4°C). The supernatant was collected and transferred 583 
into autosampler glass vials, which were stored at -80°C until further analysis. Samples 584 
were randomized in order to avoid bias due to machine drift and processed blindly. LC-585 
MS analysis was performed using a QExactive Orbitrap mass spectrometer coupled to 586 
a Dionex U3000 UHPLC system (Thermo). The liquid chromatography system was 587 
fitted with a Sequant ZIC-pHILIC column (150 mm × 2.1 mm) and guard column (20 mm 588 
× 2.1 mm) from Merck Millipore (Germany) and temperature maintained at 40°C. The 589 
mobile phase was composed of 20 mM ammonium carbonate and 0.1% ammonium 590 
hydroxide in water (solvent A), and acetonitrile (solvent B). The flow rate was set at 200 591 
µL/min with the gradient as described previously 32. The mass spectrometer was 592 
operated in full MS and polarity switching mode. The acquired spectra were analyzed 593 
using XCalibur Qual Browser and XCalibur Quan Browser software (Thermo Scientific). 594 
 595 
596 
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Statistical analysis 597 
One and two-tailed Student’s t-test were used to compare independent means. 598 
Statistical analysis was performed using Prism 5 software.  599 
 600 
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